Merck halts ph. 2 Alzheimer’s trial after Neuphoria small molecule underwhelms

Merck & Co. has nixed the phase 2 study of a potential Alzheimer’s disease medicine after the drug underwhelmed in an interim analysis, marking another blow for the pharma’s struggling partner Neuphoria Therapeutics.